Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female in good general health~* Must have presbyopia~Exclusion Criteria:~* History of allergic reaction to the study drug or any of its components~* Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- BRIMOCHOL™ PF (Type: EXPERIMENTAL): A single drop in each eye at a visit.
- Carbachol PF (Type: ACTIVE_COMPARATOR): A single drop in each eye at a visit.
- Brimonidine tartrate (Type: ACTIVE_COMPARATOR): A single drop in each eye at a visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).